ONCAlert | Upfront Therapy for mRCC
Videos  >  

Discussing Reimbursement Barriers for FLT3 Mutation Analysis

Jordan Clark
Published Online:4:00 PM, Thu July 11, 2019


FLT3 mutation analysis in laboratories has brought on reimbursement barriers in clinical oncology. Jordan Clark, chief commercial officer, Diaceutics, a diagnostic development and commercialization company, spoke to Targeted Oncology about the cause of reimbursement issues and how the problem affects all parties involved.

Historically, FLT3 mutation analyses were processed slowly, and fewer tests were being ordered. Today’s laboratories, however, often operate on a 24-hour basis to handle a large number of tests in a shorter period of time. For these expedient labs, the cost of testing is much higher. Such expenses are not covered for reimbursement, says Clark.

By educating those involved in the testing process, including laboratories, physicians, and payers, a consensus can be reached around a more appropriate turnaround time for FLT3 tests. Such education will allow physicians enough time to make clinical decisions that are best for their patients but also help the laboratories maintain a reputation for efficient FLT3 mutation analysis. In turn, finding solutions may decrease costs for payers.

The introduction of new methodologies and partnership with laboratories and other organizations already exist and are working to make improvements to reimbursement. Clark states that education in the clinical setting is still the most critical step.
Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.